Go Pro
NASDAQ:DOMH

Dominari Q2 2026 Earnings Report

Dominari logo
$2.71 -0.19 (-6.55%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$2.69 -0.02 (-0.77%)
As of 08/14/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dominari EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.34
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Dominari Revenue Results

Actual Revenue
$16.79 million
Expected Revenue
$16.79 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

Dominari Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Dominari's next earnings date is estimated for Tuesday, August 18, 2026, based on past reporting schedules.

Conference Call Resources

Dominari Earnings Headlines

Dominari (NASDAQ:DOMH) Lowered to "Sell" Rating by Wall Street Zen
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
Dominari (NASDAQ:DOMH) Trading Down 0.8% - What's Next?
See More Dominari Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dominari? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dominari and other key companies, straight to your email.

About Dominari

Dominari (NASDAQ:DOMH), a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

View Dominari Profile